39243-02-2
39243-02-2
Chemical Structure
Pyrazolam
- CAS No.: 39243-02-2
- Formula:C16H12BrN5
- Molecular Weight:354.20
IUPAC Name: 8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine
InChIKey: BGRWSFIQQPVEML-UHFFFAOYSA-N
SMILES: BrC1=CC=C2C(C(C3=NC=CC=C3)=NCC4=NN=C(C)N24)=C1
Biological Activity: Pyrazolam is a brominated triazolo benzodiazepine psychoactive substance with oral effectiveness. Pyrazolam produces anxiolytic, sedative, and sleep-promoting effects. Pyrazolam can be used for the research of anxiety[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pyrazolam | Pyrazolam is a brominated triazolo benzodiazepine psychoactive substance with oral effectiveness. Pyrazolam produces anxiolytic, sedative, and sleep-promoting effects. Pyrazolam can be used for the research of anxiety. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pyrazolam-d7 | Pyrazolam-d7 is deuterium labeled Pyrazolam. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Manchester KR, et al. The blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines. Forensic Toxicol. 2022 Jul;40(2):349-356. [Content Brief]
- [2]. Moosmann B, et al. Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom. 2013;48(11):1150-1159. [Content Brief]
- [3]. Mullin A, et al. Benzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques. Pharmacy (Basel). 2024;12(1):13. Published 2024 Jan 12. [Content Brief]
- [4]. Abouchedid R, et al. Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances-Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam-in the UK. J Med Toxicol. 2018;14(2):134-143. [Content Brief]
